[go: up one dir, main page]

NO995966L - 5-Naphthalen-1-yl-1,3-dioxane derivatives, their preparation and therapeutic use - Google Patents

5-Naphthalen-1-yl-1,3-dioxane derivatives, their preparation and therapeutic use

Info

Publication number
NO995966L
NO995966L NO995966A NO995966A NO995966L NO 995966 L NO995966 L NO 995966L NO 995966 A NO995966 A NO 995966A NO 995966 A NO995966 A NO 995966A NO 995966 L NO995966 L NO 995966L
Authority
NO
Norway
Prior art keywords
group
atom
optionally substituted
nitrogen atom
naphthalen
Prior art date
Application number
NO995966A
Other languages
Norwegian (no)
Other versions
NO995966D0 (en
Inventor
Gihad Dargazanli
Patrick Lardenois
Jonathan Frost
Pascal George
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9706944A external-priority patent/FR2764287B1/en
Priority claimed from FR9706947A external-priority patent/FR2764291B1/en
Priority claimed from FR9706945A external-priority patent/FR2764288B1/en
Priority claimed from FR9706946A external-priority patent/FR2764289B1/en
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of NO995966D0 publication Critical patent/NO995966D0/en
Publication of NO995966L publication Critical patent/NO995966L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

Forbindelse med formel (I) hvor R± representerer en alkylgruppe, V representerer et hydrogenatom, en lineær eller forgrenet alkylgruppe, en cykloalkylgruppe, en cykloalkyl- metylgruppe, en fenylalkylgruppe som eventuelt er substituert på fenylringen, en karboksymetylgruppe, en alkoksykarbonyl- metylgruppe eller en karbamoylmetylgruppe som eventuelt er substituert på nitrogenatomet, W representerer en karboksy- metylgruppe, en alkoksykarbonylmetylgruppe, en karbamoyl- metylgruppe som eventuelt er substituert på nitrogenatomet, en 4- til 7-leddet cyklisk gruppe som eventuelt inneholder et oksygenatom eller svovelatom, eller en pyridylmetylgruppe, en 1-metylpyrrolylmetylgruppe, en furylmetylgruppe, en tienylmetylgruppe eller en l,3-tiazolylmetylgruppe, eller V og W danner sammen med nitrogenatomet en pyrrolidinylgruppe, en piperidylgruppe eller en l,2,3,4-tetrahydroisokinolinyl- gruppe. Oppfinnelsen er også anvendbar i terapi.A compound of formula (I) wherein R + represents an alkyl group, V represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, a cycloalkylmethyl group, a phenylalkyl group optionally substituted on the phenyl ring, a carboxymethyl group, an alkoxycarbonylmethyl group carbamoylmethyl group optionally substituted on the nitrogen atom, W represents a carboxymethyl group, an alkoxycarbonylmethyl group, a carbamoylmethyl group optionally substituted on the nitrogen atom, a 4- to 7-membered cyclic group optionally containing an oxygen atom or sulfuryl atom, or a pyridine atom, or a 1-methylpyrrolylmethyl group, a furylmethyl group, a thienylmethyl group or a 1,3-thiazolylmethyl group, or V and W together with the nitrogen atom form a pyrrolidinyl group, a piperidyl group or a 1,2,3,4-tetrahydroisoquinolinyl group. The invention is also applicable in therapy.

NO995966A 1997-06-05 1999-12-03 5-Naphthalen-1-yl-1,3-dioxane derivatives, their preparation and therapeutic use NO995966L (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR9706944A FR2764287B1 (en) 1997-06-05 1997-06-05 5-NAPHTALEN-1-YL-1,3-DIOXANES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR9706947A FR2764291B1 (en) 1997-06-05 1997-06-05 5-NAPHTALEN-1-YL-1,3-DIOXANE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR9706945A FR2764288B1 (en) 1997-06-05 1997-06-05 5-NAPHTALEN-1-YL-1,3-DIOXANE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR9706946A FR2764289B1 (en) 1997-06-05 1997-06-05 5-NAPHTALEN-1-YL-1,3-DIOXANE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
PCT/FR1998/001113 WO1998055474A1 (en) 1997-06-05 1998-06-03 5-naphthalen-1-yl-1,3-dioxane derivatives, preparation and therapeutic application

Publications (2)

Publication Number Publication Date
NO995966D0 NO995966D0 (en) 1999-12-03
NO995966L true NO995966L (en) 2000-02-04

Family

ID=27447000

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995966A NO995966L (en) 1997-06-05 1999-12-03 5-Naphthalen-1-yl-1,3-dioxane derivatives, their preparation and therapeutic use

Country Status (18)

Country Link
EP (1) EP0986552A1 (en)
JP (1) JP2002502412A (en)
KR (1) KR20010013435A (en)
CN (1) CN1265658A (en)
AR (1) AR012908A1 (en)
AU (1) AU8025198A (en)
BG (1) BG103937A (en)
BR (1) BR9810742A (en)
CA (1) CA2290695A1 (en)
CO (1) CO4940480A1 (en)
EE (1) EE9900560A (en)
HU (1) HUP0002166A3 (en)
IL (1) IL133242A0 (en)
NO (1) NO995966L (en)
PL (1) PL337234A1 (en)
SK (1) SK166199A3 (en)
TR (1) TR199903022T2 (en)
WO (1) WO1998055474A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2003445A3 (en) * 2000-07-21 2004-08-18 Ortho@Mcneilápharmaceuticalźáinc Carbamate compounds intended for prevention or treatment of neuropathic pain and pain associated with histamine a migraine headache
FR2843964B1 (en) * 2002-08-29 2004-10-01 Sanofi Synthelabo DIOXANE-2-ALKYLCARBAMATES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0461958B1 (en) * 1990-06-15 1994-09-14 Synthelabo 2-(aminoalkyl)-5-(arylalkyl)1,3-dioxanderivatives their production and their use in therapeutics
FR2714055B1 (en) * 1993-12-22 1996-01-19 Synthelabo Derivatives of 5- (arylalkyl) -1,3-dioxane substituted in position 2, their preparation and their use in therapy.
FR2742152B1 (en) * 1995-12-06 1998-01-16 Synthelabo 5-NAPHTALEN-1-YL-1,3-DIOXANES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

Also Published As

Publication number Publication date
CN1265658A (en) 2000-09-06
EE9900560A (en) 2000-06-15
HUP0002166A2 (en) 2001-06-28
BR9810742A (en) 2000-09-12
AR012908A1 (en) 2000-11-22
EP0986552A1 (en) 2000-03-22
NO995966D0 (en) 1999-12-03
JP2002502412A (en) 2002-01-22
HUP0002166A3 (en) 2002-12-28
KR20010013435A (en) 2001-02-26
AU8025198A (en) 1998-12-21
CA2290695A1 (en) 1998-12-10
PL337234A1 (en) 2000-08-14
BG103937A (en) 2000-07-31
IL133242A0 (en) 2001-03-19
TR199903022T2 (en) 2000-04-21
WO1998055474A1 (en) 1998-12-10
CO4940480A1 (en) 2000-07-24
SK166199A3 (en) 2000-06-12

Similar Documents

Publication Publication Date Title
DE60015927D1 (en) Phenylharnstoff und phenylthioharnstoffderivate
HUP0003921A2 (en) Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
HUP0303652A2 (en) Cyclic derivatives as modulators of chemokine receptor activity and pharmaceutical compositions containing them
NZ528851A (en) N-aroyl cyclic amines
GB9917408D0 (en) Compounds
TW200505834A (en) Sulfamide derivative and the pharmaceutical composition thereof
NO872686D0 (en) NEW PHARMACOLOGICAL RELATIONS.
HUP0104867A2 (en) Heterocyclic compounds useful in the treatment of inflammatory diseases, process for their preparation, pharmaceutical compositions comprising thereof and their use
HUP0103283A2 (en) Pyrazinone protease inhibitors, pharmaceutical compositions containing them and use of the compounds
HUT74367A (en) Fungicidal alpha-aryl-substituted cyclic amide derivatives, fungicid compositions containing these as active ingredients and using thereof
MY102866A (en) Amide derivatives.
NO932005L (en) Angiotensin II antagonists
NO944911L (en) Non-peptide takykininreseptorantagonister
FR2674855B1 (en) PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION.
NO973635L (en) Method of inhibiting cell-cell adhesion
NO996108L (en) 9 oksinerytromycinderivater
HUP9802937A2 (en) Benzo[g]quuinoline derivatives, pharmaceutical compositions containing them and their use
DK306586A (en) PYRIDON CARBOXYLIC ACID DERIVATIVES AND PROCEDURES FOR PREPARING THEREOF
YU41600A (en) 2,3-substituted indole compounds as cox-2 inhibitors
HUP0001164A2 (en) Cyclic depsipeptide pf1022 derivatives
DK0652000T3 (en) Use of 2-phenyl-3-aroylbenzothiophenes for the preparation of a drug for inhibiting angiogenesis and angiogenic diseases
HUP9701588A2 (en) New flavone compounds, process for preparing them and pharmaceuticals containing them
MXPA05013631A (en) Heterocyclic methyl sulfone derivative.
UA27910C2 (en) Method of increasing thrombomodulin expression and increasing protein c activation rate
DK163581C (en) CONDENSED PYRAZOL-3-OXO PROPANNITRILL DERIVATIVES AND PROCEDURES FOR PREPARING THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THE COMPOUNDS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application